logo
Tomatoes recalled over salmonella risk

Tomatoes recalled over salmonella risk

Yahoo05-05-2025

Tomatoes have been recalled across the country over a possible salmonella risk.
Ray & Mascari Inc, announced the recall of its four packs of Vine Ripe tomatoes May 2, followed by the FDA's notice the next day. The company was notified by Hanshaw & Caping Farms in Immokalee, Florida, of the potential salmonella contamination, prompting the recall.
Potentially affected tomatoes were packaged in plastic cartons and had a VINE RIPE TOMATOES label that read "Packed by Ray & Mascari Inc."
The tomatoes were shipped to stores in New York, Illinois, Michigan, Pennsylvania, Indiana, Kentucky, Missouri, Mississippi, Tennessee, Ohio, and Wisconsin.
But that's not the only tomato recall affecting consumers.
Williams Farms Repack LLC has recalled tomatoes sold to wholesalers in South Carolina, North Carolina, and Georgia due to possible salmonella. That brings the total number of states involved across both recalls to 14.
Tomatoes were distributed between April 23 and 28, according to the FDA's notice.
No illnesses have been reported in either case.
Customers in possession of the affected tomatoes are urged to throw them out, as salmonella can cause diarrhea, stomach cramps, fever, nausea, and vomiting.
Meanwhile, several other food recalls have affected Americans in recent weeks.
Upper Crust Bakery LP issued a voluntary recall on three of its bread products after glass fragments were discovered on the surface of the loaves, according to an FDA report issued on April 12.
The recall affected 89 cases of Ancient Grains Hoagie Rolls, 699 cases of Multigrain Sourdough, and 30 cases of Whole Grain Multigrain bread. All products were sold frozen and packaged in corrugated paper cartons.
The recalled breads were sold at stores in six states: California, Connecticut, Delaware, Maryland, Ohio, and Pennsylvania.
Prior to that, a brand of celery sold at Walmart was recalled due to a listeria risk.
Duda Farm Fresh Foods, Inc. recalled its washed and ready-to-eat 4-inch/1.6 ounce Marketside Celery Sticks 'due to possibility of contamination with Listeria monocytogenes.'

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

ProZenith Launches Natural Supplement Formulated for Weight Management Support
ProZenith Launches Natural Supplement Formulated for Weight Management Support

Business Upturn

time34 minutes ago

  • Business Upturn

ProZenith Launches Natural Supplement Formulated for Weight Management Support

By GlobeNewswire Published on June 7, 2025, 06:50 IST Aurora, June 06, 2025 (GLOBE NEWSWIRE) — ProZenith recently announced the launch of its new wellness supplement developed to assist individuals in maintaining energy, focus, and mindful appetite awareness as part of a balanced and active lifestyle. Manufactured in the United States in a facility that is FDA-registered and GMP-certified, the product is now available through official online channels. ProZenith is intended for individuals pursuing support for general weight management and overall well-being. Its formulation includes select ingredients chosen to align with healthy routines and support individuals seeking help managing non-hunger-related snacking behaviors. Each purchase of ProZenith is covered by a 60-day refund policy, reflecting the company's customer-first return assurance framework. All ProZenith supplements are manufactured without genetically modified ingredients and adhere to U.S. quality standards. Production takes place in an FDA-registered facility that complies with current Good Manufacturing Practices (cGMP). ProZenith is currently available through the company's official online platform at with multiple purchase options provided for convenience. About ProZenith ProZenith develops nutritional supplements designed to support individuals on their wellness journeys. The company emphasizes high-quality manufacturing, transparency, and customer satisfaction as it continues to expand its product offerings for health-conscious consumers. For customer support inquiries, contact: [email protected] Disclaimer: This product has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Media Contact: Company: ProZenith ProZenith Address: 19655 E 35th Dr #100, Aurora, CO 80011 19655 E 35th Dr #100, Aurora, CO 80011 Email: [email protected] [email protected] Order Phone Support: (925) 217-7353 Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.

RenovoRx (RNXT) PT Raised to $11.50 by Ascendiant on Strong Q1 2025 Results
RenovoRx (RNXT) PT Raised to $11.50 by Ascendiant on Strong Q1 2025 Results

Yahoo

timean hour ago

  • Yahoo

RenovoRx (RNXT) PT Raised to $11.50 by Ascendiant on Strong Q1 2025 Results

On Thursday, Ascendiant analyst Edward Woo raised the price target on RenovoRx Inc. (NASDAQ:RNXT) to $11.50 from $11, while maintaining a Buy rating on the shares. This adjustment follows the company's strong revenue growth reported in its Q1 2025 results. Woo indicated that the commercialization of RenovoCath and anticipated positive clinical data in Q3 will serve as strong catalysts for the stock. A clinical researcher in a lab examining a new biopharmaceutical product. The Q1 result includes ~$200K in revenue from commercial sales of RenovoCath alone. RenovoCath is an FDA-cleared and dual-balloon catheter device for the targeted isolation of blood flow and delivery of fluids. R&D expenses increased to $1.7 million, up from $1.3 million in Q1 2024, which was driven by higher employee compensation and manufacturing costs during the quarter. The company's Phase 3 TIGeR-PaC clinical trial showed promising results, with patients experiencing a median overall survival of 16 months using their targeted approach compared to 10 months with standard chemotherapy. There was also a 65% reduction in adverse events like nausea and fatigue. This trial is evaluating the company's proprietary TAMP therapy platform for the treatment of Locally Advanced Pancreatic Cancer. RenovoRx Inc. (NASDAQ:RNXT) is a clinical-stage biopharmaceutical company that develops targeted combination therapies to enhance therapeutic outcomes for cancer patients undergoing treatment. While we acknowledge the potential of RNXT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store